Maxim downgraded Yield10 Bioscience to Hold from Buy. The analyst notes that while Yield10 shipped Camelina seed and harvested grain to growers and offtake partners, and received payment during the quarter, due to the small scale of the harvest which currently represents only a proof-of-concept, it has not yet capitalized inventory or recognized revenue. The firm is removing its revenue estimates and downgrading shares on uncertainty regarding its near-term commercialization prospects, Maxim tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on YTEN:
- Yield10 announces USDA-APHIS’s BRS determined Camelina can be grown in US
- USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States
- USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States
- Yield10 Bioscience reports Q3 EPS (41c), consensus (39c)
- Yield10 Bioscience Announces Third Quarter 2023 Financial Results
